Abbott Laboratories stock consolidates as bearish momentum continues after weak technical signals

Traders Union
All News
Financial News
Abbott Laboratories slides 0.15% today

Highlights

Abbott Laboratories reported Q4 earnings amid strong digital health initiatives, particularly in remote monitoring and smart devices, supporting future demand potential.
The company continues to face headwinds from pricing and reimbursement pressures as value-based care adoption increases across healthcare providers.
Shares trade under key moving averages with persistent bearish momentum; $105.00 serves as crucial support, with expected range of $105.00–$111.00 and downside risk prevailing.

Broader digital health gains offset by sector pricing and adoption pressures

Abbott Laboratories reported its fourth-quarter earnings. The company has participated in broader industry advances in digital health, including remote patient monitoring and smart devices, which were noted for their potential to drive new demand. Period challenges such as pricing and reimbursement pressures have also been highlighted as healthcare providers increase adoption of value-based care models, though price action has remained under broader selling pressure.

Oversold signals and weak trend as ABT remains under key resistance

Technical indicators for ABT continue to show persistent downside pressure, with the price remaining below all major moving averages — SMA-20, SMA-50, and SMA-200. The Ichimoku Kijun at $112.22 serves as the nearest resistance, while the momentum outlook remains bearish. The daily MACD supports a sell bias, with the ADX at 18.38 indicating a weak, non-directional trend. Oscillators such as RSI (36.69), Stoch RSI (0.00, oversold), CCI (–153.34, oversold), and BBP (–0.50, oversold) confirm an oversold state and dominant seller pressure intraday. The Awesome Oscillator reinforces the broader negative pattern. ABT opened with a minor gap up at $109.43 but slipped 0.15% from the open, now trading near the lower end of today’s $108.52 – $110.08 range under continued intraday pressure and low volatility. No positive divergence is observed across major signals.

Bearish bias persists as breakout hinges on resistance or support breach

In the short term, ABT is expected to remain within a typical volatility band relative to current levels, with a projected five-day range of $105.00 – $111.00. The probability of a meaningful price increase is below 20%, and further downside remains likely. The baseline scenario anticipates sideways trading within this corridor. A decisive move above $112.22 would be necessary to trigger a bullish scenario, while a close below $105.00 could accelerate the prevailing downtrend.

Anton Kharitonov, expert at Traders Union, notes ABT continues to lag below key moving averages with all technical momentum firmly negative. He sees little evidence of buyers stepping in, even as the stock appears oversold on several indicators. Fundamental participation in digital health has not offset prevailing seller pressure. "Unless Abbott Laboratories can reclaim $112.22, I expect the downtrend and intraday weakness to persist."

Last time, analysts noted that Abbott shares remained volatile amid a sustained downtrend, with immediate support in the $112–115 range and resistance near $118–120. Technical indicators show the Supertrend is supportive below current levels, while continued recovery will require a decisive move above resistance to shift momentum.

Source of Data: ABT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.